{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011227","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.705700+00:00","generated_at":"2026-05-17T15:05:48.712623+00:00","sec_items":["1.01","2.02","2.03","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Armata posts Q2 2025 operating loss; announces positive AP-SA02 trial results and $15M credit from Innoviva","bullets":["Q2 2025 operating loss of $6.8M vs. $11.9M loss in Q2 2024; cash at $4.3M as of June 30, 2025.","Entered $15M secured credit agreement with Innoviva at 14% interest, matures Jan 2029; proceeds to fund AP-SA02 development.","Positive topline results from Phase 1b/2a diSArm trial: met primary endpoints, improved clinical outcomes, no treatment-related SAEs.","Received additional $4.65M non-dilutive funding from U.S. Department of Defense through MTEC.","Plans end-of-Phase 2 meeting with FDA in H2 2025; expects to start Phase 3 pivotal trial in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011227","json":"https://secwatch.observer/filing/0001558370-25-011227.json","markdown":"https://secwatch.observer/filing/0001558370-25-011227.md","text":"https://secwatch.observer/filing/0001558370-25-011227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/0001558370-25-011227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/armp-20250811x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:05:48.712623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed9630bf2cff9d3a3296c286aa1b817593b63e14","claim":"Armata Pharmaceuticals, Inc. incurred term loan of $15 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 11, 2029.","evidence_excerpt":"The August 2025 Credit Agreement provides for a secured term loan facility in an aggregate amount of $15 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/0001558370-25-011227-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$15 million"},{"label":"Counterparty","value":"Innoviva Strategic Opportunities LLC"},{"label":"Rate","value":"14.0% per annum"},{"label":"Maturity","value":"January 11, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}